Please login to the form below

Not currently logged in

Astellas appoints Dr Songlin Xue head of global pharmacovigilance

He joins from Takeda and was formerly at Novartis and Wyeth

Dr Songlin Xue has moved to Astellas Pharma to take up the US-based role of head of global pharmacovigilance (PV).

He will work out of the Japanese pharma company's Northbrook, Illinois headquarters for the Americas and report to Astellas chief medical officer Sef Kurstjens.

Dr Xue has spent more than 20 years in the pharmaceutical industry, most recently at Takeda, where he was senior vice president, head global pharmacovigilance.

Prior to joining Takeda, Dr Xue held posts with a number of global pharmaceutical companies, including Novartis and Wyeth. 

Astellas president and CEO Yoshihiko Hatanaka said: “I am pleased that Dr Xue will be joining us at Astellas as head of global pharmacovigilance. Dr Xue's knowledge and experience will help the company pursue its operational excellence and further enhance our global PV and product compliance capabilities.”

16th April 2013

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...